FindTrial
Sign In

Efficacy of once-weekly Semaglutide 1mg versus once-weekly Tirzepatide on glycemic control measured by continuous glucose monitoring in adults with type 2 diabetes

Efficacy of once-weekly Semaglutide 1mg versus once-weekly Tirzepatide on glycemic control measured by continuous glucose monitoring in adults with type 2 diabetes - Efficacy of once-weekly Semaglutide 1mg versus once-weekly Tirzepatide on glycemic control measured by continuous glucose monitoring in adults with type 2 diabetes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000051349
Enrollment
40
Registered
2023-06-20
Start date
2023-06-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

Once-weekly Semaglutide 1mg Once-Weekly Tirzepatide(Doze escalation)

Sponsors

Tochigi Medical Center Shimotsuga
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Type 2 diabetes over 20 years old Patients who have been treated with Semaglutide 1mg Patients with HbA1c 6.5% or more and less than 10.5% Patients with BMI 22kg/m2 or more

Exclusion criteria

Exclusion criteria: Patients diagnosed with type 1 diabetes Patients with a history of chronic pancreatitis or acute pancreatitis Patients with severe infections Patients in need of surgery Other patients deemed inappropriate by the physician

Design outcomes

Primary

MeasureTime frame
Proportion of Time In Range at Week 24—

Secondary

MeasureTime frame
Proportion of Time In Tight Range at Week 24. Others of Glycemic indicator(MAGE,CV,MODD,CONGA2,IQR) Change in body composition from baseline to week 24(Muscle mass, body fat mass, lean body mass, body water mass, skeletal muscle mass index)—

Countries

Japan

Contacts

Public ContactYasutake Shinohara

Tochigi Medical Center Shimotsuga Diabetes and Endocrinology

yasutake@dokkyomed.ac.jp0282-22-2551

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026